Together, our results should motivate further research, assessing the exact mechanisms by which αSyn may accelerate the Aβ-tau axis, which could help us understand how to prevent the transition from amyloidosis to tauopathy in AD and potentially establish αSyn co-pathology as a treatment target in AD. The gene discussed is MAPT; the disease is Alzheimer disease.